The Long Read / Belgium: The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Belgium s.a. – n.v.
Park Lane G, Culliganlaan 2G
1831 Diegem
Belgium
Phone: +32 2 219 12 18
Fax: +32 2 219 23 56
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Belgium is a vitally important country for Johnson & Johnson’s pharmaceutical arm, Janssen, globally. In addition to their R&D centre and a pharma production plant in Beerse, Janssen also has…
Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship…
Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of metrics including a relatively high number of hospital beds per capita (six per…
Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics…
Axel De Muyt, general manager & VP of Novo Nordisk Belgium and Luxembourg, recounts his journey through the pharma industry, how he has been able to revive the company’s perspectives…
In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA)…
GSK, the world’s largest manufacturer of vaccines, has pursued a different strategy to that of its contemporaries in the effort to develop a safe, effective, and mass-producible COVID-19 vaccine. PharmaBoardroom…
Alexander Alonso, general manager of medtech giant BD’s operations in Belgium, the Netherlands, and Luxembourg outlines the company’s extensive footprint in the region, how it has rapidly mobilised in the…
Philippe de Pougnadoresse, country president & general manager pharma for Novartis Belgium & Luxembourg, outlines his affiliate’s fast and comprehensive response to the COVID-19 crisis, what can be learned from…
Vincent Stephenne, managing director of Belgian CDMO BePharBel Manufacturing, highlights the company’s innovative approach to developing new galenic forms for existing molecules, its growth trajectory thus far, and his future…
Christophe Van Damme, vice president and general manager of Perrigo Belgium and Luxembourg, shines a light on the transformation for Perrigo since its acquisition of Omega Pharma in 2015. Van…
See our Cookie Privacy Policy Here